COMPARE · Data as of August 21, 2026
HRMY vs INVA
Verdict: Side-by-side breakdown using the Bull Rankings model. HRMY scored 88.7, INVA scored 68.6 — HRMY leads.
Compare another set
HRMY
Harmony Biosciences Holdings, Inc.
88.7
$38.15 · $2.2B
fundamentals as of
Score gap
20.1
HRMY leads
INVA
Innoviva, Inc.
68.6
$21.07 · $1.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestINVA4.9x
- Fastest growthHRMY+24.3%
- Strongest balance sheetHRMY0.16
- Highest qualityHRMY80 / 100
- Largest discount to fair valueHRMY-75%
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
HRMY
stronger →← stronger
INVA
80
Qualityreturns · margins · balance sheet
69
91
Growthrevenue & earnings expansion
49
95
Valuevaluation vs sector peers
95
HRMY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
HRMY
INVA
$355mC
FCF
$189mC
+24.3%A-
Rev
+18.8%B+
0.16B+
D/E
0.27B
12.3xA
P/E
4.9xA
0.44A
PEG
0.31A
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
HRMY
INVA
75% below
Price vs fair valuelower is cheaper
59% below
~-18%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-11%/yr
+206%
1-yr DCF upside
+106%
+303%
5-yr DCF upside
+142%
+506%
10-yr DCF upside
+205%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
HRMY
Why this score
- Durable high returns
INVA
Why this score
- Diluting shareholders
The companies
HRMYHarmony Biosciences Holdings, Inc.
Why now
Biotechnology · market cap $2.2b. 7% off the 52-week high of $40.87. Revenue growing +24%, comfortably above the S&P median. PEG 0.44 — paying under fair value for the growth rate. 10 sell-side analysts rate this a Buy with a mean 1-yr target of $46.10 (implying +21% upside).
Moat
Net margin 19% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 196% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
INVAInnoviva, Inc.
Why now
Biotechnology · market cap $1.5b. 16% off the 52-week high of $25.15. Revenue growing +19%, comfortably above the S&P median. PEG 0.31 — paying under fair value for the growth rate. 4 sell-side analysts rate this a Buy with a mean 1-yr target of $35.00 (implying +66% upside).
Moat
Net margin 81% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 29% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where HRMY and INVA diverge
On the headline score the gap is 20.1 points in favor of HRMY. The widest single difference is Growth, where HRMY leads by 42.3 points.
- GrowthHRMY 91.5 · INVA 49.2HRMY +42.3
- QualityHRMY 79.9 · INVA 69.0HRMY +10.9
- ValueHRMY 95.4 · INVA 95.2level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.